Maravai is a holding company. Through its subsidiaries, Co. operates as a life sciences company that provides products to enable the development of drug, therapies, diagnostics, vaccines, and support research on human diseases. Co. operates in two segments: Nucleic Acid Production, which includes messenger ribonucleic acid, long and short oligonucleotides, its CleanCap® capping technology and oligonucleotide building blocks; and Biologics Safety Testing, which sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The MRVI average annual return since 2020 is shown above.
The Average Annual Return on the MRVI average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MRVI average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRVI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|